

Peter Dorfmann^{1/4}aller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8377857/publications.pdf>

Version: 2024-02-01

60
papers

6,971
citations

94415

37
h-index

138468

58
g-index

61
all docs

61
docs citations

61
times ranked

6320
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology. <i>Annals of Cardiothoracic Surgery</i> , 2022, 11, 106-119.	1.7	17
2	Interplay of sex hormones and long-term right ventricular adaptation in a Dutch PAH-cohort. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 445-457.	0.6	12
3	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. <i>Nature Reviews Cardiology</i> , 2022, 19, 314-331.	13.7	46
4	Group 3 Pulmonary Hypertension: From Bench to Bedside. <i>Circulation Research</i> , 2022, 130, 1404-1422.	4.5	19
5	Pulmonary veno-occlusive disease associated with long-term occupational exposure to chemical solvents and pesticides. A case report. <i>Respiratory Medicine and Research</i> , 2022, , 100943.	0.6	0
6	Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2021, 144, 52-73.	1.6	38
7	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2021, 41, 1549-1562.	3.8	3
8	Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9105.	4.1	10
9	ERS statement on chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2002828.	6.7	287
10	Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2021, 30, 210161.	7.1	5
11	Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 148-157.	5.6	53
12	Pulmonary capillary haemangiomas: a distinct entity?. <i>European Respiratory Review</i> , 2020, 29, 190168.	7.1	17
13	NADPH oxidase subunit NOX1 is a target for emphysema treatment in COPD. <i>Nature Metabolism</i> , 2020, 2, 532-546.	11.9	23
14	Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary veno-occlusive disease. <i>Pulmonary Circulation</i> , 2020, 10, 1-4.	1.7	4
15	Comparison of Human and Experimental Pulmonary Venous Occlusive Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 63, 118-131.	2.9	24
16	Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation. <i>Circulation</i> , 2019, 140, 1409-1425.	1.6	54
17	Capillary density in right ventricular myocardium in congenital heart disease. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 328-331.	0.6	1
18	Pulmonary vascular disease and pulmonary hypertension. <i>Diagnostic Histopathology</i> , 2019, 25, 304-312.	0.4	18

#	ARTICLE	IF	CITATIONS
19	Pulmonary Arterial Histologic Lesions in Patients With COPD With Severe Pulmonary Hypertension. <i>Chest</i> , 2019, 156, 33-44.	0.8	37
20	Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. <i>European Respiratory Journal</i> , 2019, 53, 1801887.	6.7	776
21	Inhibition of B cell-dependent lymphoid follicle formation prevents lymphocytic bronchiolitis after lung transplantation. <i>JCI Insight</i> , 2019, 4, .	5.0	28
22	Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. <i>Cardiovascular Research</i> , 2018, 114, 880-893.	3.8	52
23	Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic <i>EIF2AK4</i> Mutations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 537-541.	5.6	12
24	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. <i>European Respiratory Journal</i> , 2018, 51, 1700745.	6.7	136
25	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 647-655.	0.6	50
26	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. <i>European Heart Journal</i> , 2017, 38, ehw597.	2.2	83
27	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 125-134.	10.7	123
28	The importance of capillary density-stroke work mismatch for right ventricular adaptation to chronic pressure overload. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 2070-2079.	0.8	15
29	Phenotypic Characterization of <i>EIF2AK4</i> Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017, 136, 2022-2033.	1.6	111
30	Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model". <i>Circulation</i> , 2016, 133, e592-3.	1.6	4
31	<i>BMPR2</i> mutation status influences bronchial vascular changes in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016, 48, 1668-1681.	6.7	68
32	Pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2016, 47, 1518-1534.	6.7	289
33	Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1273-1285.	5.6	88
34	Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2016, 133, 1747-1760.	1.6	75
35	The Pathobiology of Chronic Thromboembolic Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2016, 13, S215-S221.	3.2	121
36	Resident PW1 ⁺ Progenitor Cells Participate in Vascular Remodeling During Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2016, 118, 822-833.	4.5	34

#	ARTICLE	IF	CITATIONS
37	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2016, 133, 1371-1385.	1.6	141
38	Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet. <i>Journal of Visualized Experiments</i> , 2015, , e53133.	0.3	13
39	Chemotherapy-Induced Pulmonary Hypertension. <i>American Journal of Pathology</i> , 2015, 185, 356-371.	3.8	149
40	Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension. <i>Circulation</i> , 2015, 131, 1006-1018.	1.6	441
41	Mitomycin-Induced Pulmonary Veno-Occlusive Disease. <i>Circulation</i> , 2015, 132, 834-847.	1.6	103
42	Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 983-997.	5.6	144
43	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2015, 46, 1721-1731.	6.7	80
44	Increased Pericyte Coverage Mediated by Endothelial-Derived Fibroblast Growth Factor-2 and Interleukin-6 Is a Source of Smooth Muscle-Like Cells in Pulmonary Hypertension. <i>Circulation</i> , 2014, 129, 1586-1597.	1.6	178
45	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with <i>EIF2AK4</i> mutations. <i>European Respiratory Journal</i> , 2014, 44, 1069-1072.	6.7	43
46	Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. <i>European Respiratory Journal</i> , 2014, 44, 1275-1288.	6.7	201
47	Right ventricular plasticity in a porcine model of chronic pressure overload. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 194-202.	0.6	20
48	EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. <i>Nature Genetics</i> , 2014, 46, 65-69.	21.4	351
49	Immune Dysregulation and Endothelial Dysfunction in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 129, 1332-1340.	1.6	141
50	Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D4-D12.	2.8	465
51	Pulmonary arterial hypertension. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 97.	2.7	226
52	Cytotoxic Cells and Granulysin in Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 189-196.	5.6	54
53	Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 128, 512-523.	1.6	97
54	Pulmonary Lymphoid Neogenesis in Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 311-321.	5.6	249

#	ARTICLE	IF	CITATIONS
55	Inflammation in Pulmonary Arterial Hypertension. , 2012, , 213-229.		1
56	Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. <i>Respiratory Research</i> , 2011, 12, 119.	3.6	67
57	Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 2888-2897.	8.2	83
58	Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 81-88.	5.6	405
59	Pulmonary Veno-Occlusive Disease. <i>Medicine (United States)</i> , 2008, 87, 220-233.	1.0	295
60	Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. <i>Human Pathology</i> , 2007, 38, 893-902.	2.0	291